SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of its DNA synthesis offering with the launch of Gene Fragments with increased lengths ranging from 1.8kb to 5.0kb..

加利福尼亚州南旧金山市——（商业新闻短讯）——Twist Bioscience Corporation（纳斯达克：TWST）是一家利用其硅平台提供高质量合成DNA的公司，该公司今天宣布扩大其DNA合成产品，推出长度从1.8kb到5.0kb不等的基因片段。。

“Leveraging our Express Genes workflow, industry-leading error rate and rapid turnaround times, we continue to push the boundaries of what is possible in DNA synthesis to expand our portfolio of products that enable our customers to quickly and efficiently advance their research,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Twist Bioscience首席执行官兼联合创始人Emily M.Leproust博士说：“利用我们的Express Genes工作流程、业界领先的错误率和快速的周转时间，我们继续推动DNA合成的可能性，以扩大我们的产品组合，使我们的客户能够快速有效地推进他们的研究。”。

“Our goal is to serve all researchers no matter where they are in their customer journey, whether they are Makers, Buyers or transitioning from Makers to Buyers. With the versatility, speed, high quality, scalability, competitive pricing, and now increased length of Twist Gene Fragments, we can further penetrate the Maker's Market and meet the needs of customers who previously had to stitch together shorter fragments, as well as enable customers working in RNA therapeutic screening applications.”.

“我们的目标是为所有研究人员提供服务，无论他们在客户旅程中处于何处，无论他们是制造商、买家还是从制造商过渡到买家。凭借多功能性、速度、高质量、可扩展性、有竞争力的价格以及现在增加的Twist基因片段长度，我们可以进一步渗透制造商的市场，满足以前不得不缝合较短片段的客户的需求，并使客户能够在RNA治疗筛选应用中工作。”。

Twist’s low error rate of 1:7,500 base pairs enables the production of longer fragments that can be easily incorporated into workflows, allowing researchers to select fewer colonies for screening or to use the gene fragments directly in in vitro transcription to make RNA. The increased length of the Gene Fragment gives researchers the ability to further customize and incorporate more elements into the fragment.

Twist的1:7500碱基对的低错误率使得能够产生更长的片段，这些片段可以很容易地整合到工作流程中，从而使研究人员能够选择更少的菌落进行筛选，或者直接在体外转录中使用基因片段来制备RNA。基因片段长度的增加使研究人员能够进一步定制并将更多元素整合到片段中。

Turnaround time for all Gene Fragments starts at two business days, regardless of length..

所有基因片段的周转时间从两个工作日开始，无论长度如何。。

Twist Gene Fragments

Twist基因片段

Twist Gene Fragments are universally compatible with various downstream cloning methods, allowing for seamless integration into a wide array of applications. They can be utilized in protein engineering, antibody discovery, pathway engineering, functional genomics, diagnostic assays and other fields.

Twist基因片段与各种下游克隆方法普遍兼容，可以无缝集成到各种应用中。它们可用于蛋白质工程，抗体发现，途径工程，功能基因组学，诊断分析和其他领域。

Twist Gene Fragments are customizable and have no order limit. Turnaround time for Gene Fragments 0.3-5.0kb starts at two business days..

Twist基因片段是可定制的，没有订单限制。0.3-5.0kb基因片段的周转时间从两个工作日开始。。

About Twist Bioscience Corporation

关于Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip.

Twist Bioscience是一家领先且快速发展的合成生物学和基因组学公司，该公司开发了破坏性DNA合成平台，以实现生物学工程的工业化。该平台的核心是一项专有技术，它开创了一种通过在硅芯片上“写入”DNA来制造合成DNA的新方法。

Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery.

Twist正在利用其独特的技术制造广泛的基于DNA的合成产品，包括合成基因，用于下一代测序（NGS）制备的工具以及用于药物发现和开发的抗体库。Twist还在DNA和生物制剂药物发现的数字数据存储方面寻求长期机会。

Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research..

Twist生产的产品适用于许多行业，包括医疗保健、工业化学品、农业和学术研究。。

Follow us on LinkedIn | X | YouTube | Instagram

在LinkedIn | X | YouTube | Instagram上关注我们

Twist Bioscience Legal Notice Regarding Forward-Looking Statements

Twist Bioscience关于前瞻性声明的法律公告

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, our ability to penetrate the maker’s market, the compatibility of this product with downstream cloning methods and integration into a wide array of applications.

本新闻稿包含前瞻性声明。除历史事实陈述外，本文所载的所有陈述均为前瞻性陈述，反映了管理层根据1995年《私人证券诉讼改革法案》的安全港条款所做出的当前信念和期望，包括但不限于我们渗透制造商市场的能力、本产品与下游克隆方法的兼容性以及与广泛应用的集成。

Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

前瞻性陈述涉及已知和未知的风险、不确定性和其他重要因素，这些因素可能导致Twist Bioscience的实际结果、表现或成就与前瞻性陈述所表达或暗示的任何未来结果、表现或成就有重大差异。

Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period will depend heavily on the success of our existing products and the development and commercialization of additional products in the synthetic biology, biologic drug and data storage industries; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to ach.

这些风险和不确定性包括实现Twist Bioscience重组活动预期收益的能力以及减少DNA数据存储投资的能力；吸引新客户、保留和增加现有客户销售额的能力；Twist Bioscience在任何特定时期获得足够收入以实现或维持运营或盈利的正现金流的能力将在很大程度上取决于我们现有产品的成功以及合成生物学，生物药物和数据存储行业其他产品的开发和商业化；快速变化的技术的风险和不确定性以及合成生物学中可能使产品扭曲的广泛竞争生物科学正在发展过时或无竞争力；重要客户保留的不确定性；Twist Bioscience成功整合被收购公司和ach的能力。